Skip to main content
Veterinary Medicines

Versifel CVR-T Lyophilisat und Suspension zur Herstellung einer Injektionssuspension für Katzen

Authorised
  • Rabies virus, strain Flury LEP, Inactivated
  • Feline calicivirus, strain F9, Live
  • Felid herpesvirus 1, strain FVRm, Live
  • Feline panleucopenia virus, Live

Product identification

Medicine name:
Versifel CVR-T Lyophilisat und Suspension zur Herstellung einer Injektionssuspension für Katzen
Active substance:
  • Rabies virus, strain Flury LEP, Inactivated
  • Feline calicivirus, strain F9, Live
  • Felid herpesvirus 1, strain FVRm, Live
  • Feline panleucopenia virus, Live
Target species:
  • Cat
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Rabies virus, strain Flury LEP, Inactivated
    3.25
    international unit(s)
    /
    1.00
    millilitre(s)
  • Feline calicivirus, strain F9, Live
    316228.00
    tissue culture infective dose 50
    /
    1.00
    Dose
  • Felid herpesvirus 1, strain FVRm, Live
    100000.00
    tissue culture infective dose 50
    /
    1.00
    Dose
  • Feline panleucopenia virus, Live
    1000.00
    tissue culture infective dose 50
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate and suspension for suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Cat
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI06AH05
Authorisation status:
  • Valid
Authorised in:
  • Germany
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Zoetis Deutschland GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • Zoetis Belgium
Responsible authority:
  • Paul-Ehrlich-Institut
Authorisation number:
  • 64a/87
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
German (PDF)
Published on: 26/04/2022
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."